Tonix Pharmaceuticals (TNXP) and Makana Therapeutics announced a collaborative research agreement under which Tonix and Makana will study Tonixs anti-CD40L monoclonal antibody candidate, TNX-1500, in combination with Makanas human-compatible organs and cells for the treatment of organ failure. The goal of the preclinical studies is to support the submission of an investigational new drug application to the FDA to support compassionate use for patients undergoing xenotransplantation.
TNX-1500 is an investigational, humanized Fc-modified IgG4 anti-CD40L antibody with high affinity for the CD40 ligand.
Shares of Tonix Pharmaceuticals are up 3% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com